939 related articles for article (PubMed ID: 27169771)
1. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
[TBL] [Abstract][Full Text] [Related]
2. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528
[TBL] [Abstract][Full Text] [Related]
3. Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients.
Barrio AV; Downs-Canner S; Edelweiss M; Van Zee KJ; Cody HS; Gemignani ML; Pilewskie ML; Plitas G; El-Tamer M; Kirstein L; Capko D; Patil S; Morrow M
Ann Surg Oncol; 2020 May; 27(5):1617-1624. PubMed ID: 31820212
[TBL] [Abstract][Full Text] [Related]
4. Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers.
Mamtani A; Zabor EC; Stempel M; Morrow M
Ann Surg Oncol; 2019 Oct; 26(10):3269-3274. PubMed ID: 31342363
[TBL] [Abstract][Full Text] [Related]
5. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
[TBL] [Abstract][Full Text] [Related]
6. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
[TBL] [Abstract][Full Text] [Related]
7. Does a Positive Axillary Lymph Node Needle Biopsy Result Predict the Need for an Axillary Lymph Node Dissection in Clinically Node-Negative Breast Cancer Patients in the ACOSOG Z0011 Era?
Pilewskie M; Mautner SK; Stempel M; Eaton A; Morrow M
Ann Surg Oncol; 2016 Apr; 23(4):1123-8. PubMed ID: 26553439
[TBL] [Abstract][Full Text] [Related]
8. The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype.
Pilewskie M; Zabor EC; Mamtani A; Barrio AV; Stempel M; Morrow M
Ann Surg Oncol; 2017 Nov; 24(12):3527-3533. PubMed ID: 28762114
[TBL] [Abstract][Full Text] [Related]
9. Patient Age and Tumor Subtype Predict the Extent of Axillary Surgery Among Breast Cancer Patients Eligible for the American College of Surgeons Oncology Group Trial Z0011.
Ong CT; Thomas SM; Blitzblau RC; Fayanju OM; Park TS; Plichta JK; Rosenberger LH; Hyslop T; Shelley Hwang E; Greenup RA
Ann Surg Oncol; 2017 Nov; 24(12):3559-3566. PubMed ID: 28879416
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
11. Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy.
Tadros AB; Moo TA; Stempel M; Zabor EC; Khan AJ; Morrow M
Breast Cancer Res Treat; 2020 Feb; 180(1):197-205. PubMed ID: 31938938
[TBL] [Abstract][Full Text] [Related]
12. Is Preoperative Axillary Imaging Beneficial in Identifying Clinically Node-Negative Patients Requiring Axillary Lymph Node Dissection?
Pilewskie M; Jochelson M; Gooch JC; Patil S; Stempel M; Morrow M
J Am Coll Surg; 2016 Feb; 222(2):138-45. PubMed ID: 26711795
[TBL] [Abstract][Full Text] [Related]
13. Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis.
Yoo TK; Kang BJ; Kim SH; Song BJ; Ahn J; Park WC; Chae BJ
Breast Cancer Res Treat; 2020 Jun; 181(2):403-409. PubMed ID: 32328848
[TBL] [Abstract][Full Text] [Related]
14. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
[TBL] [Abstract][Full Text] [Related]
15. Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 Patients.
Morrow M; Van Zee KJ; Patil S; Petruolo O; Mamtani A; Barrio AV; Capko D; El-Tamer M; Gemignani ML; Heerdt AS; Kirstein L; Pilewskie M; Plitas G; Sacchini VS; Sclafani LM; Ho A; Cody HS
Ann Surg; 2017 Sep; 266(3):457-462. PubMed ID: 28650355
[TBL] [Abstract][Full Text] [Related]
16. Extranodal Tumor Deposits in the Axillary Fat Indicate the Need for Axillary Dissection Among T1-T2cN0 Patients with Positive Sentinel Nodes.
Mamtani A; Barrio AV; Goldman DA; Wen HY; Vincent A; Morrow M
Ann Surg Oncol; 2020 Oct; 27(10):3585-3592. PubMed ID: 32488512
[TBL] [Abstract][Full Text] [Related]
17. Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy.
Dengel LT; Van Zee KJ; King TA; Stempel M; Cody HS; El-Tamer M; Gemignani ML; Sclafani LM; Sacchini VS; Heerdt AS; Plitas G; Junqueira M; Capko D; Patil S; Morrow M
Ann Surg Oncol; 2014 Jan; 21(1):22-7. PubMed ID: 23975314
[TBL] [Abstract][Full Text] [Related]
18. Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort.
Jung J; Han W; Lee ES; Jung SY; Han JH; Noh DY; Kim Y; Choi HJ; Lee JE; Nam SJ; Lee JW; Kim HJ; Um E; Kim JH; Park S; Cho YU
Breast Cancer Res Treat; 2019 May; 175(1):203-215. PubMed ID: 30715659
[TBL] [Abstract][Full Text] [Related]
19. Applicability of the ACOSOG Z0011 criteria in women with high-risk node-positive breast cancer undergoing breast conserving surgery.
Chung A; Gangi A; Mirocha J; Giuliano A
Ann Surg Oncol; 2015 Apr; 22(4):1128-32. PubMed ID: 25300606
[TBL] [Abstract][Full Text] [Related]
20. Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Nguyen TT; Hoskin TL; Day CN; Degnim AC; Jakub JW; Hieken TJ; Boughey JC
Ann Surg Oncol; 2018 Sep; 25(9):2596-2602. PubMed ID: 29978369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
